Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
- Registration Number
- NCT01176916
- Lead Sponsor
- Pfizer
- Brief Summary
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \& are switched to Aromasin® for completion of a total of 5 consecutive years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since then, there is currently lack of systematic collection and analysis for the efficacy and safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Interventional Study is being proposed to collect data systematically and to assess the efficacy and safety of Aromasin® adjuvant setting in Chinese population.
- Detailed Description
This is interventional study and single arm study. N/A
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 564
- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.
- ER positive.
- The patient must be postmenopausal woman.
- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will necessarily precede and will be independent of the decision to enroll patients in the study).
- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin® treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.
- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin®).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description A Aromasin (exemestane) -
- Primary Outcome Measures
Name Time Method Time-to-Event 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) An event was defined as the earliest occurrence of any of the following: 1) Loco-regional/distant recurrence of the primary breast cancer (BC) (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause.
- Secondary Outcome Measures
Name Time Method Incidence Rate of Each Event 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) Incidence rate (per annum) of the event was defined as a ratio of the number of events and the total exposure time (in years) to Aromasin therapy.
Percentage of Participants Experiencing Each Event 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) An event was defined as the following: 1) Loco-regional/distant recurrence of the primary breast cancer (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause.
Harzard Ratio: the Relationship Between Multiple Disease Variables and Time-to-Event 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) A Cox proportional hazards regression model with stepwise selection was used to evaluate the influence of multiple disease variables on the time-to-event. The disease variables in the initial model included Eastern Cooperative Oncology Group \[ECOG\] performance status at diagnosis; and Tumor, Lymph Node and Metastasis \[TNM\] stage at initial diagnosis. The ECOG Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. ECOG performance status at diagnosis level included 0, 1, 2, 3 and 4, with Level 0 as the best status and Level 4 as the worst. The TNM system helps describe the size of cancer tumor and the extent to which it spreads to nearby tissues/distant parts of the body. TNM stage at initial diagnosis level included 1 (Stage I), 2 (Stage IIA), 3 (Stage IIB), 4 (Stage IIIA), 5 (Stage IIIB) and 6 (Stage IIIC), with Level 1 as the best status and Level 6 as the worst.
Number of Participants With Discontinuation Due to Adverse Events (AEs) 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) Participants permanently discontinued from the study due to AEs were counted for this outcome measure. An AE is any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The number of participants with discontinuation due to all-causality and treatment-related AEs are reported below. Treatment-related AEs were determined by the investigator.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) All-causality TEAEs were counted for this outcome measure. TEAE is defined as an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. The number of participants with all-causality and treatment-related TEAEs are reported below. Treatment-related TEAEs were determined by the investigator.
Hazard Ratio: the Relationship Between (Human Epidermal Growth Factor Receptor 2) HER2 Status and Time-to-Event 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) A Cox proportional hazards regression model was used to evaluate the relationship between HER2 status level (binary) and time-to-event (Positive vs Negative). The method for selecting factors for the Cox regression model was based on significant results at univariate analysis and the clinical judgement for the multivariate model. Stepwise method was used for the selection of final independent variables. The criteria for stepwise selection were pentry = 0.25 and pstay = 0.15.
Trial Locations
- Locations (53)
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
🇨🇳Bengbu, Anhui, China
Breast and thyroid surgery of the Central Hospital of WuHan
🇨🇳WuHan, Hubei, China
Hunan Provincial People's Hospital
🇨🇳Changsha, Hunan, China
Thyroid and breast surgery
🇨🇳Shenzhen City, Guangdong, China
China-Japan Friendship Hospital
🇨🇳Beijing, China
The first hospital of jilin university
🇨🇳Changchun, Jilin, China
SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University
🇨🇳Guangzhou, Guangdong, China
The First hospital of LanZhou university
🇨🇳Lanzhou, Gansu, China
Affiliated hospital of Guangdong medical college
🇨🇳ZhanJiang, Guangdong, China
Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology
🇨🇳Jingzhou, Hubei, China
Suzhou Municipal Hospital
🇨🇳Suzhou, Jiangsu, China
Jiangsu Province Hospital/ Surgery Department
🇨🇳Nanjing, Jiangsu, China
Breast Surgery of YanTai Yu Huang Ding Hospital
🇨🇳Yan Tai, Shandong, China
The Affiliated Hospital of inner Mongolia medical university
🇨🇳Hu He Hao Te, Inner Mongolia, China
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Henan provincial people's hospital
🇨🇳Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China
Xiangya Hospital Central South University /Department of Breast
🇨🇳Changsha, Hunan, China
Changzhou No.2 People's Hospital
🇨🇳Changzhou, Jiangsu, China
Jiangsu Cancer Hospital/ Surgery Department
🇨🇳Nanjing, Jiangsu, China
Jinling Hospital
🇨🇳Nanjing, Jiangsu, China
Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery
🇨🇳Nanjing, Jiangsu, China
The Fourth Affiliated Hospital Of China Medical University
🇨🇳ShenYang, Liaoning, China
The Affiliated Hospital of Qingdao University
🇨🇳Qingdao, Shandong, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Qingdao municipal Hospital
🇨🇳Qingdao, Shandong, China
West China Hospital, Sichuan University/ Oncology Department
🇨🇳Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
🇨🇳Chengdu, Sichuan, China
Affiliated Hospital of North Sichuan Medical College
🇨🇳Nanchong, Sichuan, China
Tianjin Cancer Hospital/Breast cancer department
🇨🇳Tianjin, Tianjin, China
Affiliated Cancer Hospital of Xinjiang Medical University
🇨🇳Urumchi, Xinjiang, China
Yunnan Cancer Hospital
🇨🇳Kunming, Yunnan, China
Fifth Medical Center of the PLA General Hospital
🇨🇳Beijing, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Cancer Hospital Chinese Academy of medical sciences
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Peking University Third Hospital/Department of Oncology
🇨🇳Beijing, China
Fudan University Shanghai Cancer center/Department of Breast Surgery
🇨🇳Shanghai, China
Second Affiliated hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
The First Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China
Fourth Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
🇨🇳Shantou, Guangdong, China
Hainan General Hospital
🇨🇳Haikou, Hainan, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University
🇨🇳Weihui, Henan, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Linyi People's Hospital
🇨🇳Linyi, Shandong, China
Breast and thyroid surgery of Central Hospital of Zibo
🇨🇳Zibo, Shandong, China
Breast Surgery of The Weifang People's Hospital
🇨🇳Weifang, Shandong, China
Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
🇨🇳Shanghai, China
Yangpu District Central Hospital
🇨🇳Shanghai, China
The First Affiliated Hospital of The Fourth Military Medical University
🇨🇳Xi'an, Shaanxi, China